Alopecia areata (AA) is common causes of non-scarring hair loss. Recently, a relationship with inflammatory bowel disease (IBD) was observed. Herein, we introduced cases of AA in patients with IBD. Six patients were diagnosed with AA and IBD. Three presented with alopecia totalis (AT), two presented with patchy-type AA, and one demonstrated acute diffuse and total alopecia. The most frequent type of IBD was ulcerative colitis (UC), except for one Crohn’s disease. The onset of AA relative to that of IBD was mixed; AA developed previously in all adolescents. Only one was receiving anti-tumor necrosis factor-alpha agents for IBD treatment and the hair loss worsened. Patients with patchy-type AA demonstrated favorable outcomes rather than patients with AT. This study confirmed that the ratio of AT and UC was high, suggesting that alopecia is more strongly associated with UC.Also, we emphasize the importance of careful observation of IBD symptoms in patients with AA, especially in adolescents.

Alopecia areata (AA) is common causes of non-scarring hair loss. Recently, a relationship with inflammatory bowel disease (IBD) was observed. Herein, we introduced cases of AA in patients with IBD. Six patients were diagnosed with AA and IBD. Three presented with alopecia totalis (AT), two presented with patchy-type AA, and one demonstrated acute diffuse and total alopecia. The most frequent type of IBD was ulcerative colitis (UC), except for one Crohn’s disease. The onset of AA relative to that of IBD was mixed; AA developed previously in all adolescents. Only one was receiving anti-tumor necrosis factor-alpha agents for IBD treatment and the hair loss worsened. Patients with patchy-type AA demonstrated favorable outcomes rather than patients with AT. This study confirmed that the ratio of AT and UC was high, suggesting that alopecia is more strongly associated with UC.Also, we emphasize the importance of careful observation of IBD symptoms in patients with AA, especially in adolescents.

Alopecia areata (AA) is common causes of non-scarring hair loss. Recently, a relationship with inflammatory bowel disease (IBD) was observed. Herein, we introduced cases of AA in patients with IBD. Six patients were diagnosed with AA and IBD. Three presented with alopecia totalis (AT), two presented with patchy-type AA, and one demonstrated acute diffuse and total alopecia. The most frequent type of IBD was ulcerative colitis (UC), except for one Crohn’s disease. The onset of AA relative to that of IBD was mixed; AA developed previously in all adolescents. Only one was receiving anti-tumor necrosis factor-alpha agents for IBD treatment and the hair loss worsened. Patients with patchy-type AA demonstrated favorable outcomes rather than patients with AT. This study confirmed that the ratio of AT and UC was high, suggesting that alopecia is more strongly associated with UC.Also, we emphasize the importance of careful observation of IBD symptoms in patients with AA, especially in adolescents.

Alopecia areata (AA) is common causes of non-scarring hair loss. Recently, a relationship with inflammatory bowel disease (IBD) was observed. Herein, we introduced cases of AA in patients with IBD. Six patients were diagnosed with AA and IBD. Three presented with alopecia totalis (AT), two presented with patchy-type AA, and one demonstrated acute diffuse and total alopecia. The most frequent type of IBD was ulcerative colitis (UC), except for one Crohn’s disease. The onset of AA relative to that of IBD was mixed; AA developed previously in all adolescents. Only one was receiving anti-tumor necrosis factor-alpha agents for IBD treatment and the hair loss worsened. Patients with patchy-type AA demonstrated favorable outcomes rather than patients with AT. This study confirmed that the ratio of AT and UC was high, suggesting that alopecia is more strongly associated with UC.Also, we emphasize the importance of careful observation of IBD symptoms in patients with AA, especially in adolescents.

Background: Primary cicatricial alopecia (PCA) is a rare disease that causes irreversible destruction of hair follicles and affects the quality of life (QOL). Objective: We aimed to investigate the disease awareness, medical use behavior, QOL, and real-world diagnosis and treatment status of patients with PCA. Methods: A self-administered questionnaire was administered to patients with PCA and their dermatologists. Patients aged between 19 and 75 years who visited one of 27 dermatology departments between September 2021 and September 2022 were included. Results: In total, 274 patients were included. The male-to-female ratio was 1:1.47, with a mean age of 45.7 years. Patients with neutrophilic and mixed PCA were predominantly male and younger than those with lymphocytic PCA. Among patients with lymphocytic PCA, lichen planopilaris was the most common type, and among those with neutrophilic PCA, folliculitis decalvans was the most common type. Among the total patients, 28.8% were previously diagnosed with PCA, 47.0% were diagnosed with PCA at least 6 months after their first hospital visit, 20.0% received early treatment within 3 months of disease onset, and 54.4% received steady treatment. More than half of the patients had a moderate to severe impairment in QOL. Topical/intralesional steroid injections were the most common treatment. Systemic immunosuppressants were frequently prescribed to patients with lymphocytic PCA, and antibiotics were mostly prescribed to patients with neutrophilic PCA. Conclusion This study provides information on the disease awareness, medical use behavior, QOL, diagnosis, and treatment status of Korean patients with PCA. This can help dermatologists educate patients with PCA to understand the necessity for early diagnosis and steady treatment.

Background: Alopecia areata (AA) is a chronic disease with an unpredictable course and can have a severe psychological impact on an individual. Objective: To provide evidence and consensus-based statements regarding the treatment of patients with AA in Korea. Methods: We searched for relevant studies from inception to May 2021 regarding the systemic treatment of AA. Evidence-based recommendations were also prepared. The evidence for each statement was graded and classified according to the strength of the recommendations. Hair experts from the Korean Hair Research Society (KHRS) voted on the statement, and an agreement of 75% or greater was considered as having reached consensus. Results: Current evidence supports the efficacy of systemic corticosteroids, oral cyclosporine monotherapy or combination with systemic corticosteroids, and oral Janus kinase inhibitors in severe AA patients. Systemic steroids may be considered for pediatric patients with severe AA. A consensus was achieved in three out of nine (33.3%), and one out of three (33.3%) statements pertaining to systemic treatment in adult and pediatric AA, respectively. Conclusion The present study produced up-to-date, evidence-based treatment guidelines for AA associated with the consensus obtained by experts based on the Korean healthcare system.

Background: Alopecia areata (AA) is a chronic disease with an unpredictable disease course and severe psychological impact. Objective: To provide evidence- and consensus-based insights regarding the treatment of patients with AA in Korea. Methods: We searched for relevant studies on the topical and device-based treatment of AA in the literature from inception until May 2021. Evidence-based recommendations were also prepared. The evidence for each statement was graded and classified according to the strength of the recommendations. Hair experts from the Korean Hair Research Society (KHRS) voted on the statements, and an agreement of 75% or greater was considered as consensus. Results: Currently, there remains a scarcity of topical treatments, which is supported by robust evidence from a number of high-quality randomized controlled trials. Current evidence supports the efficacy of topical corticosteroids, corticosteroid intralesional injection, and contact immunotherapy in AA patients. Topical corticosteroids and contact immunotherapy are recommended for pediatric AA. A consensus was achieved in 6 out of 14 (42.8%), and 1 out of 5 (20.0%) statements pertaining to topical and device-based treatments in AA, respectively. The expert consensus was from a single country, and the study may not cover all the treatments used. Conclusion The present study provides up-to-date, evidence-based treatment guidelines for AA based on the consensus reached among experts after considering regional healthcare circumstances, adding diversity to the previous guidelines.

Background: Injectable soft tissue fillers are important elements in facial rejuvenation as they provide volume restoration without significant inconvenience to the patient or substantial associated recovery time. Complications can be classified into immediate, delayed, or late adverse reactions. Most complications are temporary and common throughout the filler classes. Objective: To describe the long-term side effects of fillers. Methods: A retrospective study of 10 patients who experienced long-term side effects of soft tissue filler injections between 2007 and 2018 was conducted. A long-term reaction was defined as a complication that occurred 1 year after soft tissue filler injection at any facial site. Results: Ten patients were included in the study. All the patients visited our department because of a palpable subcutaneous nodular lesion on their face. The mean duration from receiving the filler injection to the appearance of side effects was 4.3 years (range, 1∼12 years). Based on their clinicopathological features, complications were roughly classified into granulomatous inflammation (60.0%), non-inflammatory palpable nodule formation (20.0%), abscess (10.0%), and dermal fibrosis with inflammation (10.0%). Conclusion Regardless of the filler type, side effects can appear up to 12 years after injection. The most common type is a granulomatous lesion; however, it can appear as a non-granulomatous lesion. Therefore, when a patient visits with a nodule or an edematous lesion without any recall reason, careful history taking is needed to find any associated clues. With close follow-up and appropriate treatment, complications associated with injectable soft tissue fillers can be limited and competently managed.